Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.

Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J.

Cancer Discov. 2019 Jun;9(6):756-777. doi: 10.1158/2159-8290.CD-18-1040. Epub 2019 Mar 12.

PMID:
30862724
2.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

3.

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).

Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA.

Haematologica. 2014 Jan;99(1):111-5. doi: 10.3324/haematol.2013.085811. Epub 2013 Sep 27.

4.

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, Williams DA.

Blood. 2012 May 17;119(20):4708-18. doi: 10.1182/blood-2011-12-395939. Epub 2012 Apr 3.

5.

Hypomethylating agents in myelodysplastic syndromes.

Blum WG.

Clin Adv Hematol Oncol. 2011 Feb;9(2):123, 126-8. No abstract available.

PMID:
22379662
6.

Supplemental Content

Support Center